A recent survey conducted by the KFF found that one in eight American adults have used a GLP-1 agonist, a class of drugs prescribed for weight loss, to treat diabetes, or to reduce the risk of heart attack and stroke in adults with heart disease. These drugs, including Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lilly’s Mounjaro and Zepbound, are being utilized by about 6% of the population currently.
The survey also highlighted concerns about the cost of these medications, with more than 50% of respondents identifying cost or insurance coverage as their biggest concern. The high list prices of GLP-1 drugs, ranging from $900 to $1,400 per month before insurance coverage, were a major barrier for many people. Even those with some insurance coverage found it difficult to afford these medications.
When it comes to the reasons for taking GLP-1 drugs, the survey found that the majority of people used them to treat diabetes or heart disease, with only 38% using them for weight loss. However, there is a growing interest in using these drugs for weight loss, especially among younger adults. The survey showed that younger adults were more likely than older adults to report taking GLP-1 drugs solely for weight loss.
There were also disparities among racial and ethnic groups in the use of GLP-1 drugs, with higher rates seen among Black adults compared to white and Hispanic adults. Additionally, there is strong public support for broader coverage of GLP-1 drugs by Medicare, especially for weight loss purposes.
Overall, while the use of GLP-1 drugs is on the rise, cost remains a significant barrier for many people. Increased insurance coverage and affordability of these medications could potentially lead to improved health outcomes and lower healthcare costs in the long term.